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Improving Global Vascular Risk Prediction
With Behavioral and Anthropometric Factors
The Multiethnic NOMAS (Northern Manhattan Cohort Study)
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Objectives This study sought to improve global vascular risk prediction with behavioral and anthropometric factors.
Background Few cardiovascular risk models are designed to predict the global vascular risk of myocardial infarction, stroke,
or vascular death in multiethnic individuals, and existing schemes do not fully include behavioral risk factors.
Methods A randomly derived, population-based, prospective cohort of 2,737 community participants free of stroke and coro-
nary artery disease was followed up annually for a median of 9.0 years in the NOMAS (Northern Manhattan Study)
(mean age 69 years, 63.2% women, 52.7% Hispanic, 24.9% African American, and 19.9% white). A global vascular
risk score (GVRS) predictive of stroke, myocardial infarction, or vascular death was developed by adding variables to
the traditional Framingham cardiovascular variables based on the likelihood ratio criteria. Model utility was assessed
through receiver-operating characteristics, calibration, and effect on reclassification of subjects.
Results Variables that significantly added to the traditional Framingham profile included waist circumference, alcohol
consumption, and physical activity. Continuous measures for blood pressure and fasting blood sugar were used
instead of hypertension and diabetes. Ten-year event-free probabilities were 0.95 for the first quartile of GVRS,
0.89 for the second quartile, 0.79 for the third quartile, and 0.56 for the fourth quartile. The addition of behav-
ioral factors in our model improved prediction of 10-year event rates compared with a model restricted to the
traditional variables.
Conclusions A GVRS that combines traditional, behavioral, and anthropometric risk factors; uses continuous variables
for physiological parameters; and is applicable to nonwhite subjects could improve primary prevention
strategies. (J Am Coll Cardiol 2009;54:2303–11) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.047c
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mardiovascular diseases remain major threats to the future
ublic health of multiple countries. Although success has
een achieved in reducing mortality, the aging of the
opulation and the lack of reduction in risk factor preva-
ence will require more innovative approaches to prevent
rom the *Department of Neurology, Miller School of Medicine, University of
iami, Miami, Florida; and the Departments of †Neurology, ‡Biostatistics, §Socio-
edical Science, and Medicine, Columbia University, College of Physicians and
urgeons, and Mailman School of Public Health, New York, New York. This work
s supported by grants from the National Institute of Neurological Disorders and
troke (R01 NS 29993). Dr. Sacco has received consulting fees from Boehringer
ngelheim for work on clinical trials of secondary stroke prevention. Dr. Elkind
eceives research support from Bristol-Myers Squibb-Sanofi and diaDexus, Inc.;
onsulting fees from Boehringer-Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Jar-
ik Heart, Novartis, and Pfizer; and lecturing honoraria from Bristol-Myers Squibb-
anofi and Boehringer-Ingelheim. This work was presented in part at the Interna-
ional Stroke Conference, New Orleans, Louisiana, February 17, 2006.c
Manuscript received March 17, 2009; revised manuscript received July 15, 2009,
ccepted July 20, 2009.ardiovascular disease and stroke. Approaches to predict
ho is at increased vascular risk can aid health care
rofessionals to detect the at-risk individual. The use of risk
ssessment tools has been recommended to help identify
ndividuals who could benefit from therapeutic interven-
ions and who may not be treated on the basis of any one
isk factor (1). Such tools should consider a broader per-
pective and attempt to estimate the global risk of develop-
ng myocardial infarction (MI), stroke, or vascular death.
Various tools have been devised to predict a variety of
dverse cardiovascular events with increasing sophistication.
owever, many of these studies have been limited by the
se of a single sex (2–4), lack of racial diversity (4–6), or
nd points limited to either heart disease (3,6,7) or stroke
lone (4,5,8,9). The Framingham-based models are the
ost widely studied tools to predict the risk of developingoronary heart disease (6), stroke (5), and cardiovascular risk
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Improving Global Vascular Risk Prediction December 8, 2009:2303–11(10); however, they do not in-
clude many behavioral variables
or anthropometric indexes. Al-
though derived from a white
population, the Framingham
model has been found to be rel-
atively accurate in certain ethnic
populations (11), but questioned
in others (12–15). There are no
prediction models derived from
cohorts with a significant non-
white population.
Our goals were to develop a
odel using the NOMAS (Northern Manhattan Study)
o improve on currently available global cardiovascular
isease risk prediction tools by incorporating both tradi-
ional and behavioral risk factors and to determine the
ncremental benefit of adding these risk factors. We
anted to develop a prediction tool from a racially and
thnically diverse cohort that would be useful for
frican-American and Hispanic people at risk for vascu-
ar disease.
ethods
he NOMAS trial is a prospective, population-based co-
ort of 3,298 subjects. The primary goals of the study are to
escribe the prevalence of vascular risk factors and incidence
f vascular outcomes in a community-based sample, to
dentify new vascular risk factors, and to characterize these
actors among a racially and ethnically diverse cohort. The
tudy was approved by the institutional review boards of
olumbia University and the University of Miami, and
nformed consent was obtained from all participants.
ohort selection. The cohort was recruited between 1993
nd 2001 as described elsewhere (16). Subjects were en-
olled if they: 1) were at least 40 years of age; 2) lived in a
re-defined geographic area of northern Manhattan for at
east 3 months in a household with a telephone; and 3) did
ot have a history of stroke. Additionally, 561 subjects with
aseline coronary artery disease (angina, MI, cardiac bypass
urgery, or coronary angioplasty) were excluded from this
nalysis. Subjects were contacted by using random digit
ialing of both published and unpublished telephone num-
ers. The telephone response rate was 91% (9% refused to
e screened), and 87% of eligible subjects indicated they
ere willing to participate. The enrollment response rate
as 75%, resulting in an overall response rate of 68%.
aseline assessment. All participants underwent a thor-
ugh baseline examination including comprehensive medi-
al history, physical examination, review of medical records,
nd fasting blood samples. Standardized questions were
dapted from the Centers for Disease Control and Preven-
ion Behavioral Risk Factor Surveillance System. Race-
thnicity was based on self-identification modeled after the
Abbreviations
and Acronyms
AIC  Akaike Information
Criterion
AUC  area under the
curve
GVRS  global vascular
risk score
MI  myocardial infarction
ROC  receiver-operator
characteristic.S. census. Smoking was defined as either nonsmoker, aurrent smoker (within the last year), or former smoker.
lcohol use, with nondrinking as the reference, was defined
s moderate if the subject asserted to currently drinking at
east 1 drink per month, but no more than 2 drinks per day.
eisure-time physical activity was recorded using a simple
uestionnaire adapted from the National Health Interview
urvey and categorized as either none (reference), mild, or
oderate-to-heavy based on the types of activities per-
ormed (17).
Blood pressure and waist circumference were measured at
aseline. Other cardiovascular conditions were recorded,
ncluding atrial fibrillation, valvular heart disease, and pe-
ipheral vascular disease (defined by self-report as a history
f vascular disease in the legs or pain in the back of the legs
ith walking that stops with rest). Fasting high-density
ipoprotein and total cholesterol were obtained using a
itachi 705 automated spectrophotometer (Boehringer
annheim, Mannheim, Germany), and low-density li-
oprotein levels were derived from the Friedwald equation.
rospective follow-up. Subjects were followed up annually
y telephone. Only 2 subjects were completely lost to
ollow-up after their baseline examination, and the average
nnual contact rate was 99%. The telephone interview
ssessed any change in vital status, neurological or cardiac
ymptoms and events, and hospitalizations. A positive
creen for any potential cardiac or neurological event was
ollowed up by an in-person assessment to determine
hether a vascular outcome had occurred. We prospectively
creened all admissions and discharges to detect hospital-
zations and outcomes that may not have been captured by
elephone interview. Nearly 70% of our vascular events led
o hospitalizations at Columbia-Presbyterian Hospital.
lassification of outcomes. Hospital records were re-
iewed to classify all outcomes as previously reported (16).
he 3 main outcomes of interest included stroke, MI, and
ascular death. At least 2 stroke neurologists were respon-
ible for verifying and classifying every case of stroke.
yocardial infarction was defined by criteria from the
ardiac Arrhythmia Suppression trial (18) and the Lipid
esearch Clinics Coronary Primary Prevention trial (19)
nd adjudicated by a study team cardiologist. Death was
lassified as either vascular or nonvascular based on infor-
ation from family, medical records, death certificate, and
rimary care physicians. Vascular causes of death were
troke, MI, heart failure, pulmonary embolus, cardiac ar-
hythmia, and other vascular causes. Nonvascular causes of
eath included accidents, cancer, pulmonary (pneumonia,
hronic obstructive pulmonary disease), and other nonvas-
ular causes.
tatistical analysis. MODEL BUILDING. Our goal was to
onstruct a survival model to predict combined cardiovascular
utcomes, which included stroke (ischemic or intracerebral
emorrhage), MI, and vascular death. We started Cox propor-
ional hazard models by including all of the traditional risk
actors from the Framingham models. Although certain vari-
bles were less predictive in our cohort, we chose to retain
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December 8, 2009:2303–11 Improving Global Vascular Risk Predictionhem because our goal was to build a predictor model
dding to the traditional Framingham variables. Some
raditional variables were used in a different functional form:
iabetes was replaced by a continuous measure of fasting
lood sugar, and dichotomous smoking status was trichoto-
ized as never, past, and current smoking. We replaced the
raditional categorical risk factors with continuous variables
o enhance the fit of the model. We evaluated the goodness
f fit of using continuous measures instead of categorical
ariables and whether the specified linear relationship on log
azard function was appropriate by generating smoothed
urve fit of martingale residuals omitting each continuous
ariable (20).
We retained basic sociodemographic variables (age, sex,
nd race-ethnicity) and selectively added other vascular risk
actors that could be ascertained through history or blood
ests. Variables that were assessed included sibling history of
troke or MI, waist circumference, body mass index, waist-
o-hip ratio, alcohol consumption, physical activity, periph-
ral vascular disease, atrial fibrillation, valvular heart disease,
omocysteine, white blood cell count, and creatinine levels.
e kept risk factor variables with significant contribution to
he fit using the likelihood ratio criterion. All 2-way interaction
erms, including by age, sex, and race-ethnicity, were examined
nd the terms contributing significantly to the fit by the
ikelihood ratio criterion are included in the final model.
A global vascular risk score (GVRS) was computed by
umming a product of a linear predictor from our final
aseline Characteristics of the NOMAS CohortTable 1 Baseline Characteristics of the NOMAS Cohort
Overall (n  2,737) His
Age (yrs), mean (SD) 68.8 (10.4)
Sex
Men 1,006 (36.8)
Women 1,731 (63.2)
Behavioral
Moderate alcohol consumption 929 (34.0)
Former smoking 954 (34.9)
Current smoking 491 (18.0)
Moderate-to-heavy physical activity 237 ( 8.7)
Cardiovascular
Systolic BP (mm Hg), mean (SD) 143 (21)
Diastolic BP (mm Hg), mean (SD) 83 (11)
Fasting blood sugar (mg/dl), mean (SD) 104.6 (47.4)
Diabetes 552 (20.2)
Waist circumference (inches), mean (SD) 36.6 (5.0)
Peripheral vascular disease 354 (12.9)
Antihypertensive medications 1,089 (40.3)
Total cholesterol (mg/dl), mean (SD) 203 (40)
HDL (mg/dl), mean (SD) 47 (15)
Outcome events
All vascular events 525 (19.2)
Stroke 190 (6.9)
Myocardial infarction 158 (5.8)
Vascular death 314 (11.5)alues are presented as n (%) unless otherwise indicated.
BP  blood pressure; HDL  high-density lipoprotein; NOMAS  Northern Manhattan Study.odel. Kaplan-Meier curves for survival free of stroke, MI,
r vascular death were plotted for the quartiles of the
VRS. We constructed plots of probabilities of having the
ombined event within 5 years and 10 years as a function of
he GVRS.
ODEL ASSESSMENTS. We reported a deviance analysis to
uantify the relative contribution of the newly added
ariables to the goodness of fit that used the additive
roperty of the sum of squares (21). We compared the
eceiver-operator characteristic (ROC) curves for our
ew model, a model with only traditional variables, and
nother model developed using an automated model
election method (Akaike Information Criterion [AIC])
22). To select the model using the AIC method, we
xamined all of the models that had additional risk factor
ariables beyond the traditional variable set and all
ossible 2-way interactions. We compared the areas
nder the curves (AUC) for these 3 models. Using every
inear predictor value as a cutoff, we formed a 2  2 table
failure/no failure vs. above/below cutoff) to obtain sen-
itivity and 1 minus specificity. To handle censoring, we
alculated sensitivity by Kaplan-Meier estimates for sur-
ival. After sorting values by false positives, areas of
uccessive trapezoids were summed to compute the AUC.
e compared the degree of subject reclassification between a
odel with traditional variable coefficients derived for our
ohort and our new model by constructing a cross-tabulation of
(n  1,443) Black (n  681) White (n  546) p Value
.9 (9.5) 1.6 (10.5) 72.9 (10.2) 0.0001
1 (37.5) 225 (33.0) 207 (37.9) 0.0268
2 (62.5) 456 (67.0) 339 (62.1)
1 (30.6) 220 (32.3) 246 (45.2) 0.0001
6 (32.3) 243 (35.7) 225 (41.2) 0.0021
9 (16.6) 161 (23.7) 79 (14.5) 0.0001
2 (6.4) 57 (8.4) 77 (14.1) 0.0001
3 (21) 147 (21) 139 (19) 0.0001
4 (11) 84 (12) 80 (11) 0.0001
.0 (51.2) 104.1 (47.4) 99.0 (35.8) 0.0104
7 (22.0) 152 (22.4) 72 (13.2) 0.0001
.8 (4.5) 36.8 (5.5) 36.1 (5.6) 0.0079
3 (14.1) 92 (13.5) 54 (9.9) 0.0436
1 (40.9) 324 (48.2) 172 (31.5) 0.0001
2 (40) 201 (39) 208 (39) 0.0067
4 (13) 52 (16) 49 (15) 0.0001
6 (14.3) 181 (26.6) 128 (23.4) 0.0001
1 (6.3) 66 (9.7) 31 (5.7) 0.0079
5 (4.5) 32 (4.7) 57 (10.4) 0.0001
9 (7.6) 117 (17.2) 81 (14.8) 0.0001panic
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Improving Global Vascular Risk Prediction December 8, 2009:2303–11redicted probability categories (10%, 10% to 20%, 20%
ver 10 years) for the 2 models (2,23).
We report 2 statistics: 1) predictability based on categor-
cal outcome whether the reclassification is correct; and
) predictability based on continuous degree of correct
eclassification. We constructed a novel graphical ap-
roach to compare the 2 predicted probabilities derived
rom the models and evaluate whether the classification
as correct or not based on the 10-year outcome of the
ubject (24,25). We calculated a modified version of the
ntegrated discrimination improvement measures pro-
osed by Pencina et al. (24) by weighting each improve-
ent based on the actual observed proportion of uncen-
ored and censored data. To conduct hypothesis testing
f equal predictability between the 2 models, we gener-
ted the null distribution of the statistic by computing
redicted probabilities of the traditional variables and
redicted probabilities of the same model from a boot-
trap sample, and repeating this procedure 1,000 times. We
lso compared Hosmer-Lemeshow statistics to check 10-year
vent predictability accounting for censoring using the Breslow
stimator as an alternative to Kaplan-Meier.
esults
he cohort consisted of 2,737 community subjects free of
troke and known coronary artery disease. The majority
f the subjects (63.2%) were women, and 52.7% were
ispanic, 24.9% were African American, and 19.9% were
hite. Baseline characteristics are shown in Table 1.
ased on the recruitment telephone data, our nonre-
ponse analysis showed that subjects who were enrolled in
erson had a similar frequency of diabetes, smoking, and
oderate alcohol use but were more likely to be over-
eight than subjects who did not participate. After a
edian follow-up of 9.0 years, 166 ischemic strokes, 24
emorrhagic strokes, 158 MIs, and 314 vascular deaths
ere observed.
Variables in the final NOMAS global vascular risk model
re shown in Table 2. Newly added significant variables
ncluded the behavioral risk factors of alcohol consumption
nd physical activity and the anthropometric variable of
aist circumference. To improve precision, our final model
sed continuous variables rather than dichotomous variables
or blood pressure and blood sugar. Martingale residuals
lots showed a gradual increasing trend supporting the use
f continuous variables. The Framingham model included
n interaction for systolic blood pressure and antihypertension
edications, whereas our model had only an interaction term
or diastolic blood pressure and antihypertensive medications.
he only other 2-way interaction term was for male sex and
oderate physical activity. None of the other 2-way interac-
ions involving our risk variables and sex or race-ethnicity had
p value 0.10, suggesting that we did not need separate risk
odels for each sex or race-ethnic group. aIn the NOMAS cohort, GVRS ranged from 4.4 to 11.6
mean 8.6  SD 1.0). The 10-year event-free probabilities
ere 0.95 for the first quartile of GVRS, 0.89 for the second
uartile, 0.79 for the third quartile, and 0.56 for the fourth
uartile (Fig. 1). The second to fourth quartiles had signif-
cantly different survival curves from the first quartile by
og-rank tests (all p  0.0001). A GVRS of 9.0 implied a
0-year probability of 0.20, a GVRS of 6.6 implied a
0-year probability of 0.02, and a GVRS of 8.2 implied a
0-year probability of 0.10.
We tested whether the new variables added to our
odel contributed to the goodness of fit. The addition of
he traditional Framingham variables to a model with just
ge and sex accounted for 3.8% of the maximum possible
mprovement of the log likelihood (chi-square 9 degrees
f freedom, p  0.0001). Our GVRS model accounted
or 5.6% of maximum possible improvement and was
ignificantly different than the model with only tradi-
ional variables (chi-square 12 degrees of freedom, p 
.0001). The areas under the ROC curves were greatest
or our NOMAS GVRS model (0.747) compared with
he model including only traditional variables (0.736) and
ultivariate Parameter Estimates, p Values, andisk Equ ion Fro Final Cox Proportional Hazardsodel, Including All Variables for Predicting Stroke,I, or Vasc lar Death in th NOMAS Cohort
Table 2
Multivariate Parameter Estimates, p Values, and
Risk Equation From Final Cox Proportional Hazards
Model, Including All Variables for Predicting Stroke,
MI, or Vascular Death in the NOMAS Cohort
Parameter
Estimate p Value
New risk factor variables
Waist (inches) 0.02156 0.03
Moderate alcohol consumption 0.18039 0.09
Moderate-to-heavy physical activity 0.16333 0.53
Moderate-to-heavy physical activity  male sex 1.01324 0.03
Peripheral vascular disease 0.26737 0.04
Sociodemographic variables
Age (yrs) 0.08338 0.0001
Black race 0.02770 0.83
Hispanic race 0.22214 0.08
Male sex 0.37949 0.0004
Traditional risk factor variables
Systolic blood pressure (mm Hg) 0.00158 0.58
Diastolic blood pressure (mm Hg) 0.01195 0.03
Diastolic blood pressure  antihypertensive
medication
0.00247 0.04
Fasting blood sugar (mg/dl) 0.00432 0.0001
Former smoking 0.16383 0.14
Current smoking 0.69142 0.0001
Total cholesterol/HDL (mg/dl) 0.05678 0.07
OMAS global vascular risk score (GVRS)  age  0.08338  male sex  0.37949  African
merican 0.02770 Hispanic ethnicity0.22214 waist (inches) 0.02156moderate
lcohol consumption  0.18039  former smoking  0.16383  current smoking  0.69142
moderate-to-heavy physical activity0.16333moderate-to-heavy physical activitymale
ex1.01324 systolic blood pressure (mm Hg) 0.00158 diastolic blood pressure (mm Hg)
0.01195  diastolic blood pressure  antihypertensive medication  0.00247  peripheral
ascular disease  0.26737  fasting blood sugar  0.00432  total cholesterol: HDL (mg/dl) 
.05678. Probability of stroke, MI, or vascular death within 10 years 1 exp (0.0000306931
xp [GVRS]).
Abbreviations as in Table 1.third model developed using the AIC method that
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December 8, 2009:2303–11 Improving Global Vascular Risk Predictionncluded traditional variables, waist circumference, and
n interaction between alcohol use and physical activity
0.739) (Fig. 2).
The NOMAS GVRS reclassified 25.4% of subjects
lassified by the model restricted to traditional variables
Table 3). However, this does not account for whether the
eclassifications were correct. Figure 3 provides more infor-
ation by plotting predicted probabilities between the 2
ompeting models. The crude summary proportion of
orrectly reclassified points by the NOMAS GVRS com-
ared with a traditional model was 54.8%. The summary
tatistic (weighted versions of the integrated discrimination
mprovement measures proposed by Pencina et al. [24])
etween the NOMAS model and the traditional variables
odel was 8.66, and the p value computed from the
ootstrap procedure was 0.055.
A calibration of the GVRS comparing the Kaplan-Meier
0-year risks of stroke, MI, or vascular death to the
redicted probabilities by deciles of the GVRS showed
easonable agreement (Fig. 4). The Hosmer-Lemeshow
tatistic was 32.3 (p  0.0001) for the model with traditional
ariables and 23.9 (p  0.0024) for the GVRS model.
lthough our proposed model has a better fit than one with
raditional variables, the Hosmer-Lemeshow statistic suggests
hat there are additional factors needed to explain the variabil-
ty of outcomes, particularly among the highest-risk group.
iscussion
lthough numerous tools have been developed for the
Figure 1 Survival Free of Stroke, Myocardial Infarction, or Vasc
The global vascular risk score (GVRS): first quartile, 4.4 to 8.0; second quartile,
8.0 to 8.7; third quartile, 8.7 to 9.3; fourth quartile, 9.3 to 11.6. NOMAS  Northurpose of estimating risk of coronary heart disease alone or stroke alone, risk prediction models for combined vascular
utcomes (stroke, MI, vascular death) may be more useful
10). This is increasingly relevant because most of our
urrent preventative medications, such as antiplatelet agents
nd statins, prevent MI and stroke. Moreover, stroke and
I may be considered hard end points, be less likely to be
nfluenced by subjective components or socioeconomic
iases, have a greater combined public health impact, and be
f particular relevance in the evaluation of nonwhite popu-
ations, in which stroke may be more frequent. The aim of
rimary prevention of cardiovascular disease should be to
revent both stroke and cardiac events, and a risk tool that
redicts the overall combined risk of these outcomes is a
ore comprehensive approach to primary prevention.
We have shown an improvement in the prediction of
lobal vascular risk by adding behavioral risk factors (alcohol
onsumption and physical activity) and the anthropometric
easure, waist circumference, to the traditional cardiovas-
ular profile. Waist circumference has not been included in
rior models, and was a better predictor than body mass
ndex in our cohort. Moreover, our GVRS tool used
ontinuous variables rather than categorical classifications
hat are used in other risk tools (fasting blood sugar instead
f diabetes, blood pressure instead of hypertension), which
ay provide more precise risk assessments. All of these risk
actors can be easily recorded in a primary care setting.
lthough less valid than specific quantitative measures, we
sed simple questions for self-reported physical activity and
lcohol use derived from reliable survey instruments. Just as
Death Stratified by NOMAS Model Quartiles of GVRS
anhattan Study.ular
ern Mmoking has been incorporated in most practice settings,
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Improving Global Vascular Risk Prediction December 8, 2009:2303–11ther practical lifestyle assessments could be added to
ffice-based clinical histories. Rather than use multiple
isk factor tables, we also sought to design a model
daptable to Internet-based or handheld programmable
evices. Simple online entry of the basic variables is
vailable to permit calculation of the GVRS (Fig. 5) (26).
he NOMAS score is also derived from a multiethnic
ohort, which may improve its applicability to nonwhite
ndividuals compared with those tools derived from white
r single-sex populations.
Figure 2 Comparative ROCs
The receiver-operator characteristics (ROCs) for a model consisting of Framing-
ham traditional variables, a model chosen by the Akaike Information Criterion
(AIC) method (Framingham traditional variables and waist circumference and an
interaction between alcohol use and physical activity [etmod*actmodheavy]),
and the NOMAS GVRS. The areas under the curves are: traditional variable
model, 0.736; traditional variables and waist circumference and an interaction
between alcohol use and physical activity, 0.739; NOMAS GVRS, 0.747.
Abbreviations as in Figure 1.
Comparison of the 10-Year Estimated VascularModel With Traditional Framingham Variables*Table 3 Comparison of the 10-Year EstimatModel With Traditional Framingham
10-Year Risk Traditional
Framingham Variables
10-Year Risk
<10% 10%
10%
Participants, n (%) 685 (90.61) 70
Actual event risk 2.5 1
10%–20%
Participants, n (%) 157 (20.58) 467
Actual event risk 3.8 1
20%
Participants, n (%) 14 (1.50) 118
Actual event risk 14.3 1
*The Framingham model included the following variables: age, sex,
(continuous), systolic blood pressure  antihypertensive medication use, high
Abbreviations as in Table 1.The Framingham models are well-known risk prediction
ools (5,6,10). Our model included the basic traditional
ardiovascular risk profile and other modifiable risk factors
hat were independent predictors of global vascular risk.
ur GVRS accounted for a greater percentage of the
og-likelihood and had a greater AUC in the ROC curve.
Figure 3 Comparison of 10-Year
Predicted Probabilities of GVRS
Comparison of 10-year predicted probabilities between the NOMAS GVRS and
the model with traditional variables. Points above/below the dashed line are
the subjects whose 10-year risk is predicted higher/lower with the NOMAS
GVRS compared with the model with traditional variables. Black crosses show
subjects who had events within 10 years, and red dots show those who are
free of the outcome for 10 years of follow-up. The black points above and the
red points below the dashed line represent correct reclassification. The crude
summary proportion of correctly reclassified points by the NOMAS GVRS com-
pared with the Framingham method was 54.8%. The summary statistic
(weighted versions of the integrated discrimination improvement measures pro-
posed by Pencina et al. [24]) between the NOMAS model and the traditional
variables model is 8.66, and the p value computed from the bootstrap proce-
dure is 0.055. Abbreviations as in Figure 1.
by thehe NOMAS GVRSscular Risks by the
ables* and the NOMAS GVRS
AS Model
Total Reclassified% >20%
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December 8, 2009:2303–11 Improving Global Vascular Risk Predictione caution, however, that the AUC should not be used as
model selection criterion because the AUC does not
hange unless relative standings of subjects change. Limi-
ations of using ROC curves for the purpose of variable
election are well documented (23,24). Our model correctly
eclassified 54.8% compared with predicted 10-year proba-
ilities from the model with traditional variables (p 
.055).
Other models have also been developed for cardiovascular
isease prediction. Some have included only fatal events
27,28), were intended for use in patients with stable angina
29), or have included community deprivation indexes not
eadily available in a physician’s office (30). Previous studies
ave also assessed the benefits of adding nontraditional risk
actors, such as high-sensitivity C-reactive protein (2).
ome have found that including novel factors, including
ardiovascular disease-associated biomarkers, only margin-
lly improved vascular prediction (8,31,32). Other predic-
ors were not considered in our NOMAS GVRS, including
arotid measurements, echocardiography, and more exten-
ive inflammatory markers. We thought there were advan-
ages to building an inexpensive model that could be more
idely used for screening in primary care settings, where
here is limited access to expensive testing of less proven
creening value (33).
In our cohort, the ratio of total cholesterol to high-
ensity lipoprotein was the lipid parameter with the most
ignificant p value. This ratio has been found to be predic-
ive of first events in the Framingham study, as well as used
n the QRISK score developed in the United Kingdom
30,34). Lipids seemed less predictive in our multiethnic,
lderly cohort. Serum low-density lipoprotein levels, for
xample, have been strongly correlated with heart disease,
ut their relationship with stroke is less certain (35). Our
ohort was also older than that in the Framingham study,
Figure 4 Calibration by Decile for NOMAS GVRS
Comparison of 10-year Kaplan-Meier–based (blue bars) and NOMAS model–based
predicted probabilities of stroke, myocardial infarction, or vascular death events bnd the effects of dyslipidemia on coronary heart disease oay diminish with age (36,37). Moreover, the inclusion of
n anthropometric measure, missing in the traditional
ramingham cardiovascular profile, may have improved risk
rediction and substituted for the effects of lipids (38,39).
We did not detect interactions for most of our vascular
isk factors with age, sex, or race-ethnicity, other than an
nteraction between physical activity and sex. Therefore, we
id not need to use separate models for men and women or
y race-ethnic group. The interaction between physical
ctivity and sex indicated that men had a greater protection
rom moderate to heavy physical activity than women.
lthough 3 different race-ethnic groups were represented,
here may have been insufficient power to detect interactions
nd identify racial differences among risk factors. Moreover,
thnic differences were attenuated by the addition of the
ther vascular risk factors. Similar to the Framingham
odel, the NOMAS GVRS also contains an interaction
erm for blood pressure and treatment indicating a greater
isk among those on treatment that likely is caused by the
everity of the condition (5,10). The reason for the better
elationship between global vascular risk and diastolic,
ompared with systolic, blood pressure is not entirely clear;
owever, we have included both measurements. Although
revious studies championed a single blood pressure com-
onent (diastolic or systolic blood pressure) as the best
redictor of cardiovascular outcomes, recent results from the
ramingham study indicate that a combination of blood
ressure components, such as systolic and diastolic blood
ressure or pulse pressure and mean arterial pressure, may
mprove stratification of risk (40).
tudy limitations. Our model did not include other car-
iovascular outcomes, such as congestive heart failure,
ngina pectoris, transient ischemic attacks, and revascular-
zation procedures, which are sometimes less well validated.
herefore, the NOMAS score may underestimate the risk
le-specific means, brown bars)
es of the NOMAS GVRS. Abbreviations as in Figure 1.(deci
y decilf all adverse cardiovascular events. The use of a single
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stimates because of regression dilution bias. We did not
ave enough repeat measurements to adequately estimate
his potential bias inherent to many prediction models.
ecause we used the entire cohort to derive the NOMAS
odel, we also were unable to validate it using other
OMAS study subjects. The accuracy and validity of this
odel will need to be validated in other independent
opulations.
onclusions
e have presented a model for assessing global vascular risk
or an urban, multiethnic population that incorporates
raditional, behavioral, and anthropometric risk factors and
ses continuous variables. With the more widespread use of
he Internet and handheld electronic devices, global vascular
isk models can provide the clinician with a simple inex-
ensive tool to stratify patients into high-, medium-, and
ow-risk groups. The adoption and more widespread use of
lobal vascular risk prediction tools that emphasize behav-
oral as well as pharmacological approaches to risk factor
anagement could greatly improve the primary prevention
Figure 5 Internet-Based Screen for Entry of GVRS
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